Press Releases

Date	Title and Summary
Toggle SummaryJune 3, 2021	DCCR ‘Worked Across the Board’ in PWS Trial, But Results Are Less Clear
Toggle SummaryJune 2, 2021	Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1a REDWOOD CITY, Calif. , June 02, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted its
Toggle SummaryJune 1, 2021	DCCR Shows ‘Life-changing’ Potential in Troubled Trial, Doctor Says in Interview
Toggle SummaryMay 21, 2021	Soleno Therapeutics to Host Webinar Highlighting DCCR for Treatment of Prader-Willi Syndrome at European Congress on Endocrinology 2021 European Key Opinion Leaders to Participate in Event REDWOOD CITY, Calif. , May 21, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the
Toggle SummaryMay 20, 2021	Soleno Therapeutics to Participate in the Oppenheimer Rare & Orphan Disease Summit REDWOOD CITY, Calif. , May 20, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present
Toggle SummaryMay 5, 2021	Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results REDWOOD CITY, Calif. , May 05, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three
Toggle SummaryMay 4, 2021	Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome Results Show Improvement in Multiple Behavioral Domains Following Treatment with DCCR Data Presented in a Poster at the Pediatric Academic Societies Annual Meeting REDWOOD CITY, Calif. , May 04, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage
Toggle SummaryApril 14, 2021	Soleno Therapeutics Participates in Prader-Willi Syndrome (PWS) DCCR Town Hall REDWOOD CITY, Calif. , April 14, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar , M.D., Chief Executive Officer,
Toggle SummaryMarch 9, 2021	Soleno to Participate in the 31st Annual Oppenheimer Healthcare Conference REDWOOD CITY, Calif. , March 09, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar , M.D., Chief Executive Officer, will
Toggle SummaryMarch 8, 2021	Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome REDWOOD CITY, Calif. , March 08, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update following recent interactions with the U.S.

Print Page RSS Feeds Email Alerts IR Contacts